News
-
Microbion Corporation said that its pravibismane inhalation suspension for the treatment of lung infections in patients with cystic fibrosis has been granted orphan drug designation by the FDA. Pravibismane inhalation suspension has already been granted… Read more . . .
-
Propeller Health announced that the FDA has granted 510(k) clearance for the company’s inhaler monitoring sensor for AstraZeneca’s Symbicort MDI. The Propeller sensor snaps on to the inhaler and connects via Bluetooth to a mobile… Read more . . .
-
Cipla said that it has received final approval for an ANDA for its generic version of Bausch’s Migranal dihydroergotamine (DHE) mesylate nasal spray for the treatment of migraine. According to Cipla, this is the company’s… Read more . . .
-
The Chinese National Medical Products Administration (NMPA) has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said. AstraZeneca’s Breztri Aerosphere budesonide/glycopyrronium/formoterol fumarate MDI was approved for the treatment of COPD by… Read more . . .
-
Covis Pharma said that it has initiated a Phase 3 of Alvesco ciclesonide MDI for the treatment of COVID-19 in US patients aged 12 and older who have not been hospitalized, with preliminary results expected… Read more . . .
-
Teva Canada said that it has imported a 4-week supply of Salamol salbutamol (albuterol) sulfate MDIs through Teva UK under an interim order by the Minister of Health in response to shortages of the inhalers in Canada caused… Read more . . .
-
Cipla has submitted an ANDA for a generic version of GSK’s Advair Diskus fluticasone propionate/salmeterol DPI in 100/50 mcg, 250/50 mcg and 500/50 dosage strengths for the treatment of asthma and COPD, the company said.… Read more . . .
-
Liquidia Technologies has announced the appointment of former Teva Pharmaceuticals Global Head of Specialty Clinical Development Tushar Shah as the company’s first Chief Medical Officer. Prior to his most recent position, Shah had served as Senior… Read more . . .
-
The organizing committee for DDL 2020, which was scheduled for December 9-11 in Edinburgh, UK, has announced the cancellation of the meeting, saying, “In addition to showcasing great new science, a major part of the… Read more . . .
-
VistaGen Therapeutics has announced that it is proposing a Phase 2a study of its PH94B aloradine nasal spray for the treatment of patients with adjustment disorder with anxiety caused by the COVID-19 pandemic, subject to approval… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA